{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T01:25:31Z","timestamp":1760318731377},"reference-count":21,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.lfs.2006.03.016","type":"journal-article","created":{"date-parts":[[2006,3,22]],"date-time":"2006-03-22T07:04:04Z","timestamp":1143011044000},"page":"1094-1099","source":"Crossref","is-referenced-by-count":4,"title":["[d-1-Nal4]endomorphin-2 is a potent \u03bc-opioid receptor antagonist in the aequorin luminescence-based calcium assay"],"prefix":"10.1016","volume":"79","author":[{"given":"Jakub","family":"Fichna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariola","family":"Piestrzeniewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Gach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Poels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Burgeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozef","family":"Vanden Broeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Janecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2006.03.016_bib1","first-page":"48","article-title":"Some quantitative uses of drug antagonists","volume":"14","author":"Arunlakshana","year":"1959","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.lfs.2006.03.016_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/bip.10399","article-title":"Dmt and opioid peptides: a potent alliance","volume":"71","author":"Bryant","year":"2003","journal-title":"Biopolymers"},{"key":"10.1016\/j.lfs.2006.03.016_bib3","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1021\/jm9706729","article-title":"Pharmacotherapies for treatment of cocaine abuse: preclinical aspects","volume":"42","author":"Carroll","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.lfs.2006.03.016_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbrc.2004.05.202","article-title":"Opioid receptor binding and in vivo antinociceptive activity of position 3-substituted morphiceptin analogs","volume":"320","author":"Fichna","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.lfs.2006.03.016_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.bcp.2004.09.011","article-title":"Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position","volume":"69","author":"Fichna","year":"2005","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.lfs.2006.03.016_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1469-8749.1995.tb11998.x","article-title":"Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians","volume":"37","author":"Gillberg","year":"1995","journal-title":"Developmental Medicine and Child Neurology"},{"key":"10.1016\/j.lfs.2006.03.016_bib7","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1021\/jm00119a019","article-title":"Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors","volume":"31","author":"Kazmierski","year":"1988","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.lfs.2006.03.016_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0003-2697(03)00354-3","article-title":"A functional assay for G-protein-coupled receptors using stably transformed insect tissue culture cell lines","volume":"320","author":"Knight","year":"2003","journal-title":"Analytical Biochemistry"},{"key":"10.1016\/j.lfs.2006.03.016_bib9","first-page":"544","article-title":"Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo","volume":"249","author":"Kramer","year":"1989","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.lfs.2006.03.016_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1399-3011.2005.00282.x","article-title":"Novel endomorphin-2 analogs with \u03bc-opioid receptor antagonist activity","volume":"66","author":"Kruszynski","year":"2005","journal-title":"Journal of Peptide Research"},{"key":"10.1016\/j.lfs.2006.03.016_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1359-6446(98)01187-8","article-title":"Design of delta-opioid peptide antagonists for emerging drug applications","volume":"3","author":"Lazarus","year":"1998","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.lfs.2006.03.016_bib12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.lfs.2006.03.016_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0960-894X(99)00652-6","article-title":"Novel Dmt-Tic dipeptide analogues as selective delta-opioid receptor antagonists","volume":"10","author":"Page","year":"2000","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.lfs.2006.03.016_bib14","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1021\/jm00161a037","article-title":"Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors","volume":"29","author":"Pelton","year":"1986","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.lfs.2006.03.016_bib15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/BF03401608","article-title":"Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides","volume":"1","author":"Salvadori","year":"1995","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.lfs.2006.03.016_bib16","doi-asserted-by":"crossref","first-page":"11871","DOI":"10.1073\/pnas.89.24.11871","article-title":"Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists","volume":"89","author":"Schiller","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.lfs.2006.03.016_bib17","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1021\/jm00073a020","article-title":"TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity","volume":"36","author":"Schiller","year":"1993","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.lfs.2006.03.016_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/(SICI)1097-0282(1999)51:6<411::AID-BIP4>3.0.CO;2-Z","article-title":"The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist\/delta antagonists","volume":"51","author":"Schiller","year":"1999","journal-title":"Biopolymers"},{"key":"10.1016\/j.lfs.2006.03.016_bib19","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1021\/jm980724+","article-title":"The opioid mu agonist\/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats","volume":"42","author":"Schiller","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.lfs.2006.03.016_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/abio.1997.2308","article-title":"A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor","volume":"252","author":"Stables","year":"1997","journal-title":"Analytical Biochemistry"},{"key":"10.1016\/j.lfs.2006.03.016_bib21","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1021\/jm0491795","article-title":"A new structural motif for mu-opioid antagonists","volume":"48","author":"Van den Eynde","year":"2005","journal-title":"Journal of Medicinal Chemistry"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320506002451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320506002451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T09:26:48Z","timestamp":1555493208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320506002451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0024320506002451"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2006.03.016","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}